Suramin sodium (suramin) dosing, indications, interactions, adverse effects, and more

Sections

Sections suramin
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for injectable solution

1g (reconstitute to100mg/mL)

Trypanosomiasis

100-200 mg (test dose) IV, then 1 g IV on days 1, 3, 7, 14, 21

TB Gambiense

10 mg/kg IV q5day to total of 12 injections

May repeat after 1 month; use concomitantly with tryparsamide

Refractory Prostate Cancer (Orphan)

Treatment of hormone-refractory prostate cancer

Orphan indication sponsor

Warner-Lambert Company
Parke-Davis Pharmaceutical Research Division; 2800 Plymouth Rd; Ann Arbor, MI 48105-2430

Dosage Forms & Strengths

powder for injectable solution

1g (reconstitute to100mg/mL)

Trypanosomiasis

20 mg/kg IV on days 1, 3, 7, 14, 21; not to exceed 1 g/dose

Frequency Not Defined

Vomiting

Urticaria

Paresthesia

Peripheral neuropathy

Kidney damage

Blood dyscrasias

Polyuria

Polydipsia

Pancytopenia

Shock

Optic atrophy

Contraindications

Hypersensitivity

Caution

Proteinuria and renal toxicity reported with use

Avoid use in renal or hepatic impairment

Pregnancy & Lactation

Pregnancy Category: no human studies conducted

Lactation: not known if excreted in breast milk

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Trypanocidal activity; inhibits enzymes involved with the oxidation of reduced NADH

Pharmacokinetics

Protein binding: 99.7%

Absorption: Poor

Vd: 90 ± 21 L (terminal phase); 38 ± 8 L (Steady state)

Half-life: 36-60 days (terminal phase)

Peak plasma concentration: >100 mcg/mL

Metabolism: None

Excretion: Urine

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]